RTTNews BiotechCodex · 实盘不做把握 7/10
北京时间·🕒 发布 12:12:17时区推断·⟳ 抓取 12:15:42·⚡ 决策 07-23 12:22:52 +7m10s·96.3 天前
三星生物二季度收入1.321万亿韩元，经营利润5860亿韩元
二季度收入1.321万亿韩元、经营利润5860亿韩元，环比仅分别增长5%和4%，属于稳健执行而非明显超预期。
📄 原文RTTNews Biotech↗ 原文
Samsung Biologics Delivers Solid Q2 2026 Growth, Operating Profit Rises
Samsung Biologics Co., Ltd. (207940.KS) reported consolidated financial results for the second quarter ended June 30, 2…
不做 Samsung Biologics（207940.KS）
财报报道已滞后近6天，收入和经营利润只是稳健环比增长，净利润同比下降8.2%，且未上修全年指引，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-17 16:34 ET · 扩散 high · price-in 风险 high ↗
关键理由
- 二季度收入1.321万亿韩元、经营利润5860亿韩元，环比仅分别增长5%和4%，属于稳健执行而非明显超预期。
- 净利润4307亿韩元同比下降8.2%，虽环比增长29.1%，但原文同时称全年15%-20%收入增长指引为维持而非上修。
- 股价截至2026-07-22收盘137.2万韩元，近20日已涨7.78%，财报新闻原发布时间为2026-07-17，当前摄取明显滞后。
主要风险
- 财报类催化通常需要相对一致预期的surprise；本文未给出超预期幅度，且部分利润指标同比下滑。
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- query_modeling_kb · 结果未知
- kb_search · 结果未知
- price_snapshot · 结果未知
原文全文
展开原文 · 2,505 字
Samsung Biologics Co., Ltd. (207940.KS) reported consolidated financial results for the second quarter ended June 30, 2026, showing continued momentum across its manufacturing network.
The company posted KRW 1,321 billion in revenue and KRW 586 billion in operating profit, compared with KRRW 1,257 billion in revenue and KRW 580 billion in operating profit in Q1 2026. This represents sequential growth of 5% in revenue and 4% in operating profit, underscoring steady demand from global biopharma clients.
Net income for Q2 2026 was KRW 430.7 billion, down 8.2% from KRW 469.2 billion in Q2 2025, but up 29.1% compared with KRW 333.6 billion in Q1 2026. EBITDA for the quarter stood at KRW 698.5 billion, compared with KRW 572.1 billion in Q2 2025, reflecting strong operational leverage.
For the first half of 2026, Samsung Biologics reported KRW 2,578 billion in revenue and KRW 1,167 billion in operating profit, with cumulative net income of KRW 899.9 billion, up 35.3% from KRW 664.9 billion in the prior-year period.
John Rim, President and CEO of Samsung Biologics said the quarter underscored "We delivered another quarter of solid execution while making meaningful progress on our growth strategy," highlighting integration of the Rockville Maryland site, expansion of the Netherlands sales office in the third quarter of 2026, and new investments through the Life Science Fund in oncology and genomics.
The company also maintained its sustainability, earning recognition in the Dow Jones Best-in-Class Indices for the fifth consecutive year.
Looking ahead, Samsung Biologics reaffirmed its full year 2026 guidance in its FY2025 results, the company projected 15-20% annual revenue growth for 2026 and announced plans to acquire PolyPeptide Group, which is expected to be completed toward the end of 2026, strengthening its capabilities in peptide therapeutics.
207940.KS has traded between KRW 1,228,000 and KRW 1,987,000 over the past year. The stock is currently trading at KRW 1,380,000, up 0.58%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 17, 2026 16:34 ET A slew of U.S. data was released during the week that threw light on trends in prices and spending. Separately, survey data reflected the consumer mood amid easing inflationary pressures. In Europe, economic output figures from the U.K. were the main news. Meanwhile, China dominated the economics news scene in Asia as the country released the latest gross domestic product and external trade data.
The company posted KRW 1,321 billion in revenue and KRW 586 billion in operating profit, compared with KRRW 1,257 billion in revenue and KRW 580 billion in operating profit in Q1 2026. This represents sequential growth of 5% in revenue and 4% in operating profit, underscoring steady demand from global biopharma clients.
Net income for Q2 2026 was KRW 430.7 billion, down 8.2% from KRW 469.2 billion in Q2 2025, but up 29.1% compared with KRW 333.6 billion in Q1 2026. EBITDA for the quarter stood at KRW 698.5 billion, compared with KRW 572.1 billion in Q2 2025, reflecting strong operational leverage.
For the first half of 2026, Samsung Biologics reported KRW 2,578 billion in revenue and KRW 1,167 billion in operating profit, with cumulative net income of KRW 899.9 billion, up 35.3% from KRW 664.9 billion in the prior-year period.
John Rim, President and CEO of Samsung Biologics said the quarter underscored "We delivered another quarter of solid execution while making meaningful progress on our growth strategy," highlighting integration of the Rockville Maryland site, expansion of the Netherlands sales office in the third quarter of 2026, and new investments through the Life Science Fund in oncology and genomics.
The company also maintained its sustainability, earning recognition in the Dow Jones Best-in-Class Indices for the fifth consecutive year.
Looking ahead, Samsung Biologics reaffirmed its full year 2026 guidance in its FY2025 results, the company projected 15-20% annual revenue growth for 2026 and announced plans to acquire PolyPeptide Group, which is expected to be completed toward the end of 2026, strengthening its capabilities in peptide therapeutics.
207940.KS has traded between KRW 1,228,000 and KRW 1,987,000 over the past year. The stock is currently trading at KRW 1,380,000, up 0.58%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 17, 2026 16:34 ET A slew of U.S. data was released during the week that threw light on trends in prices and spending. Separately, survey data reflected the consumer mood amid easing inflationary pressures. In Europe, economic output figures from the U.K. were the main news. Meanwhile, China dominated the economics news scene in Asia as the country released the latest gross domestic product and external trade data.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。